JNJ

Johnson & Johnson tops 1Q views on sales spike, but net dips
Johnson & Johnson tops 1Q views on sales spike, but net dips
Yahoo/AP
JNJ
earnings
Flag link:
JNJ's Esketamine Demonstrates Significantly Rapid Improvements in Depressive Symptoms and Suicidality in Phase 2 Study
JNJ's Esketamine Demonstrates Significantly Rapid Improvements in Depressive Symptoms and Suicidality in Phase 2 Study
CP Wire
JNJ
esketamine
depression
major depression
Flag link:
JNJ's Esketamine Demonstrates Significantly Rapid Improvements in Depressive Symptoms and Suicidality in Phase 2 Study
JNJ
esketamine
depression
major depression
Flag link:
Johnson & Johnson (JNJ) Expected to Announce Quarterly Sales of $19.38 Billion
Johnson & Johnson (JNJ) Expected to Announce Quarterly Sales of $19.38 Billion
Daily Political
JNJ
earnings
Flag link:
Q1 kicks off with J&J, Novartis, Glaxo results
Q1 kicks off with J&J, Novartis, Glaxo results
Biopharma Dive
earnings
JNJ
Novartis
GSK
Flag link:
Can Johnson & Johnson Get Its Mojo Back?
Can Johnson & Johnson Get Its Mojo Back?
Motley Fool
JNJ
Flag link:
J&J loses trial over claims linking cancer to asbestos in talc
J&J loses trial over claims linking cancer to asbestos in talc
Yahoo/Reuters
JNJ
cancer
Flag link:
Alkermes' Bad News Could Be Good News for Johnson & Johnson
Alkermes' Bad News Could Be Good News for Johnson & Johnson
Motley Fool
Alkermes
JNJ
ALKS-5461
esketamine
major depressive disorder
Flag link:
Which Big Pharma CEOs Least Deserved Their Big Pay Increases?
Which Big Pharma CEOs Least Deserved Their Big Pay Increases?
Motley Fool
Big Pharma
Pharma CEOs
executive pay
AbbVie
Bristol-Myers Squibb
Gilead Sciences
JNJ
Pfizer
Flag link:
10 Events that Rattled Medtech in 1Q18
10 Events that Rattled Medtech in 1Q18
Medical Devices and Diagnostics Industry
devices
InMode
Votiva
JNJ
diabetes
LifeScan
Orthotaxy
robotic surgery
Abbott Labs
HeartMate 3
Medtronic
Guardian Sensor 3
Edwards Lifesciences
Centera valve
SFC Fluidics
EOFlow Co
type 1 diabetes
Boston Scientific
FDA
duodenoscope
PENTAX
Fujifilm
Olympus
Theranos
Elizabeth Holmes
Flag link:
Pharma's social media strategies are growing up—and working better, too, report finds
Pharma's social media strategies are growing up—and working better, too, report finds
Fierce Pharma
social media
Novo Nordisk
JNJ
Novartis
Boehringer Ingelheim
Flag link:
Johnson & Johnson’s longest-serving CFO to retire
Johnson & Johnson’s longest-serving CFO to retire
Fierce Pharma
JNJ
Flag link:
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Flag link:
New FDA transparency push begins with J&J's Erleada
New FDA transparency push begins with J&J's Erleada
Biopharma Dive
FDA
transparency
JNJ
Erleada
drug approvals
Flag link:
Orthopedic Device Market Gains Momentum: 3 Stocks in Focus
Orthopedic Device Market Gains Momentum: 3 Stocks in Focus
Yahoo/Zacks.com
devices
Orthopedics
Stryker
Orthofix
JNJ
robotic surgery
diabetes
regulatory
Flag link:
Why Google co-founder Sergey Brin was using a robot to put sutures in synthetic tissue
Why Google co-founder Sergey Brin was using a robot to put sutures in synthetic tissue
CNBC
Google
Alphabet
devices
robotic surgery
JNJ
Verb Surgical
Flag link:
J&J says offered $2.1 billion for LifeScan diabetes unit
J&J says offered $2.1 billion for LifeScan diabetes unit
Yahoo/Reuters
JNJ
devices
diabetes
M&A
LifeScan
Flag link:
J&J’s blockbuster hopeful erdafitinib gets ‘breakthrough’ moniker
J&J’s blockbuster hopeful erdafitinib gets ‘breakthrough’ moniker
Endpoints
JNJ
erdafitinib
breakthrough therapies
metastatic urothelial cancer
Flag link:
Forget Remicade -- Here's How Johnson & Johnson Plans to Grow
Forget Remicade -- Here's How Johnson & Johnson Plans to Grow
Motley Fool
JNJ
Stelara
Zytiga
Darzalex
oncology
immunology
Flag link:
Johnson & Johnson’s Ethicon loses $35m pelvic mesh lawsuit
Johnson & Johnson’s Ethicon loses $35m pelvic mesh lawsuit
Mass Device
JNJ
Ethicon
pelvice mesh
devices
Flag link:

Pages